Immunomodulation in cancer therapeutics (Q35177553)

6 August 2017

1 reference

title

Immunomodulation in cancer therapeutics (English)

1 reference

6 August 2017

M Jane Ehrke

1

1 reference

6 August 2017

1 August 2003

1 reference

International Immunopharmacology

6 August 2017

1 reference

6 August 2017

3

1 reference

6 August 2017

8

1 reference

6 August 2017

1105-1119

1 reference

Coley's toxins, tumor necrosis factor and cancer research: a historical perspective

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Modulation of the immune response by chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Effects of chemotherapeutic agents on the immune response. I

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Effects of chemotherapeutic agents on the immune response. II

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Cellular immunological defects of chronic myelogenous leukaemics: partial dependence on busulphan therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Modification of regression of virally xenogenized tumor cells by cyclophosphamide and busulfan

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Studies on the mechanism of activation of human natural killer function by interferon and inhibitors of thymidylate synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Alteration of rat Kupffer cell function following mitomycin-C administration

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Augmentation of the generation of cell-mediated cytotoxicity in culture by mitomycin C

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

The effects of dichloro-trans-dihydroxy-bis-isopropyl-amine-platinum IV on the primary cell-mediated cytotoxic response

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Reversal by citrovorum factor of methotrexate-induced suppression of cell-mediated and humoral immune response in mouse model systems

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Potentiation of T-lymphocyte function by bleomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Selective effects of Adriamycin on murine host defense systems

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Adriamycin induced immunomodulation: dependence upon time of administration

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

1 reference

7 January 2021

Augmentation of the phagocytic activity of murine spleen cell populations induced by Adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Suppressor T cells--they're back and critical for regulation of autoimmunity!

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Histological and combined chemoimmunostimulation therapy studies against a murine leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Modulation of antitumor immunity ? Immunobiologic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Combination Interleukin-2 and Doxorubicin in Advanced Adult Solid Tumors: Circumvention of Doxorubicin Resistance in Soft-Tissue Sarcoma?

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900021-3

7 January 2021

10.1016/S1567-5769(03)00021-3

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12860167